<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM"><PMID Version="2">32862101</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>Novel Selenium-based compounds with therapeutic potential for SOD1-linked amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>102980</StartPage><MedlinePgn>102980</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">102980</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2020.102980</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(20)30356-X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease as well as Lou Gehrig's disease, is a progressive neurological disorder selectively affecting motor neurons with no currently known cure. Around 20% of the familial ALS cases arise from dominant mutations in the sod1 gene encoding superoxide dismutase1 (SOD1) enzyme. Aggregation of mutant SOD1 in familial cases and of wild-type SOD1 in at least some sporadic ALS cases is one of the known causes of the disease. Riluzole, approved in 1995 and edaravone in 2017 remain the only drugs with limited therapeutic benefits.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We have utilised the ebselen template to develop novel compounds that redeem stability of mutant SOD1 dimer and prevent aggregation. Binding modes of compounds have been visualised by crystallography. In vitro neuroprotection and toxicity of lead compounds have been performed in mouse neuronal cells and disease onset delay of ebselen has been demonstrated in transgenic ALS mice model.</AbstractText><AbstractText Label="FINDING" NlmCategory="RESULTS">We have developed a number of ebselen-based compounds with improvements in A4V SOD1 stabilisation and in vitro therapeutic effects with significantly better potency than edaravone. Structure-activity relationship of hits has been guided by high resolution structures of ligand-bound A4V SOD1. We also show clear disease onset delay of ebselen in transgenic ALS mice model holding encouraging promise for potential therapeutic compounds.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our finding established the new generation of organo-selenium compounds with better in vitro neuroprotective activity than edaravone. The potential of this class of compounds may offer an alternative therapeutic agent for ALS treatment. The ability of these compounds to target cysteine 111 in SOD may have wider therapeutic applications targeting cysteines of enzymes involved in pathogenic and viral diseases including main protease of SARS-Cov-2 (COVID-19).</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Project funding was supported by the ALS Association grant (WA1128) and Fostering Joint International Research (19KK0214) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amporndanai</LastName><ForeName>Kangsa</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Molecular Biophysics Group, Department of Biochemistry and System Biology, Institute of System, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, L69 7ZB, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Science and Engineering, University of Liverpool, Liverpool, L69 7ZD, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Seiji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience &amp; Pathobiology, Research Institute of Environmental Medicine, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan; Department of Neuroscience and Pathobiology, Nagoya University Graduate School of Medicine, Aichi, 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamanaka</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroscience &amp; Pathobiology, Research Institute of Environmental Medicine, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan; Department of Neuroscience and Pathobiology, Nagoya University Graduate School of Medicine, Aichi, 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Neill</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Science and Engineering, University of Liverpool, Liverpool, L69 7ZD, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasnain</LastName><ForeName>S Samar</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Molecular Biophysics Group, Department of Biochemistry and System Biology, Institute of System, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, L69 7ZB, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001393">Azoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054833">Isoindoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016566">Organoselenium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014763">Viral Matrix Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000705510">membrane protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>40X2P7DPGH</RegistryNumber><NameOfSubstance UI="C042986">ebselen</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001393" MajorTopicYN="N">Azoles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019281" MajorTopicYN="N">Dimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004795" MajorTopicYN="N">Enzyme Stability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054833" MajorTopicYN="N">Isoindoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056004" MajorTopicYN="N">Molecular Dynamics Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016566" MajorTopicYN="N">Organoselenium Compounds</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014763" MajorTopicYN="N">Viral Matrix Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Drug design</Keyword><Keyword MajorTopicYN="N">Ebselen</Keyword><Keyword MajorTopicYN="N">Motor neuron disease</Keyword><Keyword MajorTopicYN="N">Neurodegeneration</Keyword><Keyword MajorTopicYN="N">SOD1</Keyword></KeywordList><CoiStatement>Declaration of Interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32862101</ArticleId><ArticleId IdType="pmc">PMC7456458</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2020.102980</ArticleId><ArticleId IdType="pii">S2352-3964(20)30356-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chio A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA. Vol. 41. 2013. Global epidemiology of amyotrophic lateral sclerosis&#xa0;: a systematic review of the published literature; pp. 118&#x2013;130. (Neuroepidemiology).</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Pansarasa O, Bordoni M, Gagliardi S, Cereda C. SOD1 in amyotrophic lateral sclerosis&#xa0;: &#x201c;ambivalent&#x201d; behavior connected to the disease. Int J Mol Sci. 2018;19:1345. doi: 10.3390/ijms19051345.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19051345</ArticleId><ArticleId IdType="pmc">PMC5983710</ArticleId><ArticleId IdType="pubmed">29751510</ArticleId></ArticleIdList></Reference><Reference><Citation>Saccon RA, Bunton-stasyshyn RKA, Fisher EMC, Fratta P. Is SOD1 loss of function involved in amyotrophic lateral sclerosis&#xa0;? Brain. 2013;136:2342&#x2013;2358. doi: 10.1093/brain/awt097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt097</ArticleId><ArticleId IdType="pmc">PMC3722346</ArticleId><ArticleId IdType="pubmed">23687121</ArticleId></ArticleIdList></Reference><Reference><Citation>Juneja T, Pericak-vance MA, Laing NG, Dave S, Siddique T. Prognosis in familial amyotrophic lateral sclerosis&#xa0;: progression and survival in patients with glu100gly and ala4val mutations in Cu,Zn superoxide dismutase. Neurology. 1997;48:55&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">9008494</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Johnson JL, Agar NYR, Agar JN. Protein aggregation and protein instability govern familial amyotrophic lateral sclerosis patient survival. PLoS Biol. 2008;6:e170. doi: 10.1371/journal.pbio.0060170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0060170</ArticleId><ArticleId IdType="pmc">PMC2486295</ArticleId><ArticleId IdType="pubmed">18666828</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK. Riluzole and edaravone&#xa0;: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019;39:733&#x2013;748. doi: 10.1002/med.21528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Khleifat A Al, Meurgey J, Jones A, Leigh PN, Bensimon G. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17:416&#x2013;422. doi: 10.1016/S1474-4422(18)30054-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30054-1</ArticleId><ArticleId IdType="pmc">PMC5899963</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patient. Amyotroph Lateral Scler Front Degener. 2014;15:610&#x2013;617. doi: 10.3109/21678421.2014.959024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.959024</ArticleId><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakhit R, Crow JP, Lepock JR, Kondejewski LH, Cashman NR, Chakrabartty A. Monomeric Cu,Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic lateral sclerosis. J Biol Chem. 2004;279:15499&#x2013;15504. doi: 10.1074/jbc.M313295200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M313295200</ArticleId><ArticleId IdType="pubmed">14734542</ArticleId></ArticleIdList></Reference><Reference><Citation>Fridovich I. Superoxide dismutases. Annu Rev Biochem. 1975;44:147&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">1094908</ArticleId></ArticleIdList></Reference><Reference><Citation>Reaume AG, Elliott JL, Hoffman EK, Kowa NW, Ferrante RJ, Siwek DF. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet. 1996;13:43&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">8673102</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidlin T, Kennedy BK, Daggett V. Structural changes to monomeric CuZn superoxide dismutase caused by the familial amyotrophic lateral sclerosis-associated mutation A4V. Biophys J. 2009;97:1709&#x2013;1718. doi: 10.1016/j.bpj.2009.06.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2009.06.043</ArticleId><ArticleId IdType="pmc">PMC2749781</ArticleId><ArticleId IdType="pubmed">19751676</ArticleId></ArticleIdList></Reference><Reference><Citation>Witan H, Kern A, Koziollek-Drechsler I, Wade R, Behl C, Clement AM. Heterodimer formation of wild-type and amyotrophic lateral sclerosis-causing mutant Cu/Zn-superoxide dismutase induces toxicity independent of protein aggregation. Hum Mol Genet. 2008;17:1373&#x2013;1385. doi: 10.1093/hmg/ddn025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddn025</ArticleId><ArticleId IdType="pubmed">18211954</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng HX, Shi Y, Furukawa Y, Zhai H, Fu R, Liu E. Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proc Natl Acad Sci U S A. 2006;103:7142&#x2013;7147. doi: 10.1073/pnas.0602046103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0602046103</ArticleId><ArticleId IdType="pmc">PMC1447523</ArticleId><ArticleId IdType="pubmed">16636275</ArticleId></ArticleIdList></Reference><Reference><Citation>Auclair JR, Boggio KJ, Petsko GA, Ringe D, Agar JN. Strategies for stabilizing superoxide dismutase (SOD1), the protein destabilized in the most common form of familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2010;107:21394&#x2013;21399. doi: 10.1073/pnas.1015463107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1015463107</ArticleId><ArticleId IdType="pmc">PMC3003092</ArticleId><ArticleId IdType="pubmed">21098299</ArticleId></ArticleIdList></Reference><Reference><Citation>Banci L, Bertini I, Bla&#x17e;evit&#x161; O, Calderone V, Cantini F, Mao J. Interaction of cisplatin with human superoxide dismutase. J Am Chem Soc. 2012;134:7009&#x2013;7014. doi: 10.1021/ja211591n.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja211591n</ArticleId><ArticleId IdType="pubmed">22471402</ArticleId></ArticleIdList></Reference><Reference><Citation>Capper MJ, Wright GSA, Barbieri L, Luchinat E, Mercatelli E, Mcalary L. The cysteine-reactive small molecule ebselen facilitates effective SOD1 maturation. Nat Commun. 2018;9:1&#x2013;9. doi: 10.1038/s41467-018-04114-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-04114-x</ArticleId><ArticleId IdType="pmc">PMC5923229</ArticleId><ArticleId IdType="pubmed">29703933</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Shang H, Qiu X, Fujiwara N, Cui L, Li XM. Oxidative modification of cysteine 111 promotes disulfide bond-independent aggregation of SOD1. Neurochem Res. 2012;37:835&#x2013;845. doi: 10.1007/s11064-011-0679-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-011-0679-8</ArticleId><ArticleId IdType="pubmed">22219129</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu WC, Liang JZ, Li C, He ZX, Yuan HY, Huang BY. Pathological hydrogen peroxide triggers the fibrillization of wild-type SOD1 via sulfenic acid modification of Cys-111 article. Cell Death Dis. 2018:9. doi: 10.1038/s41419-017-0106-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-017-0106-4</ArticleId><ArticleId IdType="pmc">PMC5833406</ArticleId><ArticleId IdType="pubmed">29358575</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright GSA, Antonyuk S V., Hasnain SS. A faulty interaction between SOD1 and hCCS in neurodegenerative disease. Sci Rep. 2016;6:1&#x2013;9. doi: 10.1038/srep27691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep27691</ArticleId><ArticleId IdType="pmc">PMC4901319</ArticleId><ArticleId IdType="pubmed">27282955</ArticleId></ArticleIdList></Reference><Reference><Citation>Azad GK, Ebselen Tomar RS. a promising antioxidant drug: mechanisms of action and targets of biological pathways. Mol Biol Rep. 2014;41:4865&#x2013;4879. doi: 10.1007/s11033-014-3417-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-014-3417-x</ArticleId><ArticleId IdType="pubmed">24867080</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasago T, Peters EE, Graham DI, Masayasu H, Macrae IM. Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion. Br J Pharmacol. 1997;122:1251&#x2013;1256. doi: 10.1038/sj.bjp.0701426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0701426</ArticleId><ArticleId IdType="pmc">PMC1565026</ArticleId><ArticleId IdType="pubmed">9401794</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalayci M, Coskun O, Cagavi F, Kanter M, Armutcu F, Gul S. Neuroprotective effects of Ebselen on experimental spinal cord injury in rats. Neurochem Res. 2005;30:403&#x2013;410. doi: 10.1007/s11064-005-2615-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-005-2615-2</ArticleId><ArticleId IdType="pubmed">16018585</ArticleId></ArticleIdList></Reference><Reference><Citation>Martini F, Rosa SG, Klann IP, Fulco BCW, Carvalho FB, Rahmeier FL. A multifunctional compound ebselen reverses memory impairment, apoptosis and oxidative stress in a mouse model of sporadic Alzheimer's disease. J Psychiatr Res. 2019;109:107&#x2013;117. doi: 10.1016/j.jpsychires.2018.11.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2018.11.021</ArticleId><ArticleId IdType="pubmed">30521994</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood-Allum CA, Barber SC, Kirby J, Heath P, Holden H, Mead R. Impairment of mitochondrial anti-oxidant defence in SOD1-related motor neuron injury and amelioration by ebselen. Brain. 2006;129:1693&#x2013;1709. doi: 10.1093/brain/awl118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl118</ArticleId><ArticleId IdType="pubmed">16702190</ArticleId></ArticleIdList></Reference><Reference><Citation>Chantadul V, Wright GSA, Amporndanai K, Shahid M, Antonyuk S V. Washbourn G, et al. Ebselen as template for stabilization of A4V mutant dimer for motor neuron disease therapy. Commun Biol. 2020;3:2&#x2013;11. doi: 10.1038/s42003-020-0826-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-020-0826-3</ArticleId><ArticleId IdType="pmc">PMC7058017</ArticleId><ArticleId IdType="pubmed">32139772</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Arlene Y C, Canto MCD, Polchow CY, Alexander DD. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. 80-</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright GSA, Antonyuk S V, Kershaw NM, Strange RW, Hasnain SS. Ligand binding and aggregation of pathogenic SOD1. Nat Commun. 2013;4:1710&#x2013;1758. doi: 10.1038/ncomms2750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2750</ArticleId><ArticleId IdType="pmc">PMC3644087</ArticleId><ArticleId IdType="pubmed">23612299</ArticleId></ArticleIdList></Reference><Reference><Citation>Winter G, Waterman DG, Parkhurst JM, Aaron S, Gildea RJ, Gerstel M. DIALS&#xa0;: implementation and evaluation of a new integration package. Acta Crystallogr Sect D. 2018;D74:85&#x2013;97. doi: 10.1107/S2059798317017235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S2059798317017235</ArticleId><ArticleId IdType="pmc">PMC5947772</ArticleId><ArticleId IdType="pubmed">29533234</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans PR. An introduction to data reduction: space-group determination, scaling and intensity statistics. Acta Crystallogr Sect D Biol Crystallogr. 2011;67:282&#x2013;292. doi: 10.1107/S090744491003982X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S090744491003982X</ArticleId><ArticleId IdType="pmc">PMC3069743</ArticleId><ArticleId IdType="pubmed">21460446</ArticleId></ArticleIdList></Reference><Reference><Citation>Vagin A, Teplyakov A. Molecular replacement with MOLREP. Acta Crystallogr Sect D Biol Crystallogr. 2010;66:22&#x2013;25. doi: 10.1107/S0907444909042589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444909042589</ArticleId><ArticleId IdType="pubmed">20057045</ArticleId></ArticleIdList></Reference><Reference><Citation>Murshudov GN, Skub&#xe1;k P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr Sect D Biol Crystallogr. 2011;67:355&#x2013;367. doi: 10.1107/S0907444911001314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444911001314</ArticleId><ArticleId IdType="pmc">PMC3069751</ArticleId><ArticleId IdType="pubmed">21460454</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr Sect D Biol Crystallogr. 2004;60:2126&#x2013;2132. doi: 10.1107/S0907444904019158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444904019158</ArticleId><ArticleId IdType="pubmed">15572765</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebedev AA, Young P, Isupov MN, Moroz O V., Vagin AA, Murshudov GN. JLigand: A graphical tool for the CCP4 template-restraint library. Acta Crystallogr Sect D Biol Crystallogr. 2012;68:431&#x2013;440. doi: 10.1107/S090744491200251X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S090744491200251X</ArticleId><ArticleId IdType="pmc">PMC3322602</ArticleId><ArticleId IdType="pubmed">22505263</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Hayakawa T, Wakasugi K, Yamanaka K. Cystatin C protects neuronal cells against mutant copper-zinc superoxide dismutase-mediated toxicity. Cell Death Dis. 2014;5:1&#x2013;13. doi: 10.1038/cddis.2014.459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2014.459</ArticleId><ArticleId IdType="pmc">PMC4237269</ArticleId><ArticleId IdType="pubmed">25356866</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Ilieva H, Tamada H, Nomura H, Komine O, Endo F. Mitochondria&#x2010;associated membrane collapse is a common pathomechanism in SIGMAR 1 &#x2010; and SOD 1 &#x2010;linked ALS. EMBO Mol Med. 2016;8:1421&#x2013;1437. doi: 10.15252/emmm.201606403.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606403</ArticleId><ArticleId IdType="pmc">PMC5167132</ArticleId><ArticleId IdType="pubmed">27821430</ArticleId></ArticleIdList></Reference><Reference><Citation>Wager TT, Hou X, Verhoest PR, Villalobos A. Central nervous system multiparameter optimization desirability: application in drug discovery. ACS Chem Neurosci. 2016;7:767&#x2013;775. doi: 10.1021/acschemneuro.6b00029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.6b00029</ArticleId><ArticleId IdType="pubmed">26991242</ArticleId></ArticleIdList></Reference><Reference><Citation>Galaleldeen A, Strange R, Whitson LJ, Antonyuk S, Taylor AB, Schuermann JP. Structural and biophysical properties of metal-free pathogenic SOD1 mutants A4V and G93A. Arch Biochem Biophys. 2009;492:40&#x2013;47. doi: 10.1016/j.abb.2009.09.020.Structural.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abb.2009.09.020.Structural</ArticleId><ArticleId IdType="pmc">PMC2787720</ArticleId><ArticleId IdType="pubmed">19800308</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso RMF, Thayer MM, DiDonato M, Lo TP, Bruns CK, Getzoff ED. Insights into Lou Gehrig's disease from the structure and instability of the A4V mutant of human Cu,Zn superoxide dismutase. J Mol Biol. 2002;324:247&#x2013;256. doi: 10.1016/S0022-2836(02)01090-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2836(02)01090-2</ArticleId><ArticleId IdType="pubmed">12441104</ArticleId></ArticleIdList></Reference><Reference><Citation>Hough MA, Grossmann JG, Antonyuk S V. Strange RW, Doucette PA, Rodriguez JA, et al. Dimer destabilization in superoxide dismutase may result in disease-causing properties: Structures of motor neuron disease mutants. Proc Natl Acad Sci U S A. 2004;101:5976&#x2013;5981. doi: 10.1073/pnas.0305143101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0305143101</ArticleId><ArticleId IdType="pmc">PMC395908</ArticleId><ArticleId IdType="pubmed">15056757</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc1;lvarez-Zaldiernas C, Lu J, Zheng Y, Yang H, Blasi J, Solsona C. Cellular redox systems impact the aggregation of Cu,Zn superoxide dismutase linked to familial amyotrophic lateral sclerosis. J Biol Chem. 2016;291:17197&#x2013;17208. doi: 10.1074/jbc.M115.708230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.708230</ArticleId><ArticleId IdType="pmc">PMC5016121</ArticleId><ArticleId IdType="pubmed">27261461</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y. Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 doi: 10.1038/s41586-020-2223-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2223-y</ArticleId><ArticleId IdType="pubmed">32272481</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>